Evidence map›Paper›PMID 24715669›Full record

ArticleHepatology (Baltimore, Md.)2014

Generation of functional cholangiocyte-like cells from human pluripotent stem cells and HepaRG cells.

Noushin Dianat, Hélène Dubois-Pot-Schneider, Clara Steichen, Christophe Desterke, Philippe Leclerc, Aurélien Raveux, Laurent Combettes, Anne Weber, Anne Corlu, Anne Dubart-Kupperschmitt

Open access · hybridAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed
17.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 205 citations in OpenAlex.

  1. Review
  2. A CYP3A7 metabolically competent human induced pluripotent stem cell-derived hepatocyte-like cell (hHLCDrug metabolism and disposition: the biological fate of chemicals · 2026
    Article
  3. Article
  4. Next-Generation Hydrogels for Biliary Organoid Engineering.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  5. Bioengineered Bile Duct for Liver Regenerative Medicine and Bile Duct Reconstruction.JGH open : an open access journal of gastroenterology and hepatology · 2025
    Review
  6. Article
  7. Review
  8. Cell therapy for liver disorders: past, present and future.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Diseases of bile duct in children.World journal of gastroenterology · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Modeling Liver Development and Disease in a Dish.International journal of molecular sciences · 2023
    Review
  19. Review
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Noushin DianatINSERM, U972, Paul Brousse Hospital, Villejuif, France; Université Paris Sud, UMR-S 972, Villejuif, France; IFR 93, Bicêtre Hospital, Kremlin-Bicêtre, France; DHU Hepatinov, Paul Brousse Hospital, Villejuif, France.
Hélène Dubois-Pot-Schneider
Clara Steichen
Christophe Desterke
Philippe Leclerc
Aurélien Raveux
Laurent Combettes
Anne Weber
Anne Corlu
Anne Dubart-Kupperschmitt
Université Paris-Sud · FRBicêtre Hospital · FRInserm · FRHôpital Broussais · FRHôpital Paul-Brousse · FRUniversité de Rennes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledCholangiocytes are biliary epithelial cells, which, like hepatocytes, originate from hepatoblasts during embryonic development. In this study we investigated the potential of human embryonic stem cells (hESCs) to differentiate into cholangiocytes and we report a new approach, which drives differentiation of hESCs toward the cholangiocytic lineage using feeder-free and defined culture conditions. After differentiation into hepatic progenitors, hESCs were differentiated further into cholangiocytes using growth hormone, epidermal growth factor, interleukin-6, and then sodium taurocholate. These conditions also allowed us to generate cholangiocytes from HepaRG-derived hepatoblasts. hESC- and HepaRG-derived cholangiocyte-like cells expressed markers of cholangiocytes including cytokeratin 7 and osteopontin, and the transcription factors SOX9 and hepatocyte nuclear factor 6. The cells also displayed specific proteins important for cholangiocyte functions including cystic fibrosis transmembrane conductance regulator, secretin receptor, and nuclear receptors. They formed primary cilia and also responded to hormonal stimulation by increase of intracellular Ca(2+) . We demonstrated by integrative genomics that the expression of genes, which signed hESC- or HepaRG-cholangiocytes, separates hepatocytic lineage from cholangiocyte lineage. When grown in a 3D matrix, cholangiocytes developed epithelial/apicobasal polarity and formed functional cysts and biliary ducts. In addition, we showed that cholangiocyte-like cells could also be generated from human induced pluripotent stem cells, demonstrating the efficacy of our approach with stem/progenitor cells of diverse origins.

conclusionWe have developed a robust and efficient method for differentiating pluripotent stem cells into cholangiocyte-like cells, which display structural and functional similarities to bile duct cells in normal liver. These cells will be useful for the in vitro study of the molecular mechanisms of bile duct development and have important potential for therapeutic strategies, including bioengineered liver approaches.

Indexed as

Biliary TractBiomarkersCell Culture TechniquesCell DifferentiationCell LineageCell PolarityCells, CulturedCholagogues and CholereticsCulture MediaEmbryonic Stem CellsEpithelial CellsHepatocytesHuman Growth HormoneHumansInterleukin-6Pluripotent Stem CellsBiomarkersCholagogues and CholereticsCulture MediaHuman Growth HormoneIL6 protein, humanInterleukin-6Taurocholic Acid

Identifiers

PMID24715669
PMCPMC4315871
OpenAlexW2096502099

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.